EP3503911A4 - Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci - Google Patents

Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci Download PDF

Info

Publication number
EP3503911A4
EP3503911A4 EP17844067.3A EP17844067A EP3503911A4 EP 3503911 A4 EP3503911 A4 EP 3503911A4 EP 17844067 A EP17844067 A EP 17844067A EP 3503911 A4 EP3503911 A4 EP 3503911A4
Authority
EP
European Patent Office
Prior art keywords
analogs
albumin
making
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17844067.3A
Other languages
German (de)
English (en)
Other versions
EP3503911A1 (fr
Inventor
Joseph Y. Mo
Chun Kwong Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nal Pharmaceutical Group Ltd
Original Assignee
Nal Pharmaceutical Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/249,346 external-priority patent/US20170002057A1/en
Application filed by Nal Pharmaceutical Group Ltd filed Critical Nal Pharmaceutical Group Ltd
Publication of EP3503911A1 publication Critical patent/EP3503911A1/fr
Publication of EP3503911A4 publication Critical patent/EP3503911A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17844067.3A 2016-08-26 2017-06-27 Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci Withdrawn EP3503911A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/249,346 US20170002057A1 (en) 2015-02-26 2016-08-26 Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
PCT/US2017/039477 WO2018038803A1 (fr) 2016-08-26 2017-06-27 Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci

Publications (2)

Publication Number Publication Date
EP3503911A1 EP3503911A1 (fr) 2019-07-03
EP3503911A4 true EP3503911A4 (fr) 2020-07-29

Family

ID=61247532

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17844067.3A Withdrawn EP3503911A4 (fr) 2016-08-26 2017-06-27 Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci

Country Status (4)

Country Link
EP (1) EP3503911A4 (fr)
JP (1) JP2019534707A (fr)
SG (1) SG11201901651TA (fr)
WO (1) WO2018038803A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3932430A4 (fr) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. Composition liée à l'albumine comprenant le lrrd2 de la protéine slit3 pour la prévention ou le traitement de maladies osseuses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391376A (zh) * 2011-03-15 2012-03-28 江苏省原子医学研究所 人生长抑素十四肽与人血清白蛋白的融合蛋白及其编码基因和制备方法
CN102675467A (zh) * 2011-03-15 2012-09-19 无锡坤洲大得药业有限公司 人生长抑素二十八肽与人血清白蛋白的融合蛋白及其编码基因和制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599229A (en) * 1985-09-09 1986-07-08 International Minerals & Chemical Corp. Method of promoting animal growth using antibodies against somatostatin
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MX2010014078A (es) * 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
US20170002057A1 (en) * 2015-02-26 2017-01-05 Nal Pharmaceutical Group Limited Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391376A (zh) * 2011-03-15 2012-03-28 江苏省原子医学研究所 人生长抑素十四肽与人血清白蛋白的融合蛋白及其编码基因和制备方法
CN102675467A (zh) * 2011-03-15 2012-09-19 无锡坤洲大得药业有限公司 人生长抑素二十八肽与人血清白蛋白的融合蛋白及其编码基因和制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DING Y ET AL: "The effect of albumin fusion patterns on the production and bioactivity of the somatostatin-14 fusion protein in Pichia pastoris", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY AUGUST 2013 HUMANA PRESS USA, vol. 170, no. 7, August 2013 (2013-08-01), pages 1637 - 1648, XP002797314, DOI: 10.1007/S12010-013-0304-1 *
DING YUEDI ET AL: "The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein inPichia pastoris", JOURNAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY, BASINGSTOKE, GB, vol. 41, no. 6, 22 April 2014 (2014-04-22), pages 997 - 1006, XP035318227, ISSN: 1367-5435, [retrieved on 20140422], DOI: 10.1007/S10295-014-1440-5 *
See also references of WO2018038803A1 *

Also Published As

Publication number Publication date
JP2019534707A (ja) 2019-12-05
EP3503911A1 (fr) 2019-07-03
SG11201901651TA (en) 2019-03-28
WO2018038803A1 (fr) 2018-03-01

Similar Documents

Publication Publication Date Title
IL250622A0 (en) Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
IL260530B1 (en) Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses
EP3454832A4 (fr) Protéines de fusion gdf15 et leurs utilisations
EP3430058A4 (fr) Protéines de fusion à fab multispécifiques et leur utilisation
EP3481413A4 (fr) Protéine de fusion comprenant de la leptine et procédés de production et d'utilisation associés
EP3802812A4 (fr) Compositions de protéines de fusion ciblant l'arn et méthodes d'utilisation
EP3155018A4 (fr) Protéines de fusion à anticorps à région constante et compositions les contenant
EP3880814A4 (fr) Protéine de fusion
EP3274457A4 (fr) Protéines de fusion associées à la follistatine et leurs utilisations
EP3665194A4 (fr) Procédés basés sur l'affinité pour utiliser des protéines de liaison au récepteur de transferrine
EP3315515A4 (fr) Protéine hybride contenant un bdnf
EP3757218A4 (fr) Protéine hybride
EP3500112A4 (fr) Poudre de protéine à base de drêche de brasserie
EP3561058A4 (fr) Protéine de fusion comprenant du bdnf
EP3431506A4 (fr) Polypeptide de fusion multifonctionnel, son procédé de préparation, et son application
IL275435B (en) tatk-cdkl5 fusion proteins, preparations, formulations, and their uses
EP3253797A4 (fr) Polypeptides de fusion chimiokine-immunoglobuline, compositions, procédé de fabrication et utilisation associés
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
ZA202007491B (en) Stable fusion protein formulation
EP3257523A4 (fr) Utilisation de complexe polypeptidique en tant que vecteur de médicament polypeptidique ou protéique, procédé, et complexe de protéine hybride correspondant
EP3464384A4 (fr) Construction de protéines de fusion
EP3400228A4 (fr) Composés quadracycliques condensés, compositions et utilisations associées
EP3319930A4 (fr) Procédés et compositions pour la stabilisation de protéines
EP3503911A4 (fr) Compositions contenant une protéine hybride d'albumine et des analogues de celle-ci, procédés de production et d'utilisation de celles-ci
EP3647426A4 (fr) Protéine de fusion

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 5/02 20060101ALI20200204BHEP

Ipc: C07K 14/765 20060101ALI20200204BHEP

Ipc: A61K 38/38 20060101ALI20200204BHEP

Ipc: A61K 38/22 20060101ALI20200204BHEP

Ipc: A61K 38/31 20060101AFI20200204BHEP

Ipc: C07K 14/655 20060101ALI20200204BHEP

Ipc: A61K 38/16 20060101ALI20200204BHEP

Ipc: C12N 15/62 20060101ALI20200204BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010491

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20200626

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/22 20060101ALI20200622BHEP

Ipc: C07K 14/655 20060101ALI20200622BHEP

Ipc: A61K 38/31 20060101AFI20200622BHEP

Ipc: A61K 38/16 20060101ALI20200622BHEP

Ipc: C12N 15/62 20060101ALI20200622BHEP

Ipc: A61P 5/02 20060101ALI20200622BHEP

Ipc: A61K 38/38 20060101ALI20200622BHEP

Ipc: C07K 14/765 20060101ALI20200622BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220104